Rocket Lab’s Paradox: A Record Backlog and a Stock in Freefall
Published on 07/30/2026 at 16:01 | Redaktion boerse-global.de
The numbers tell two completely different stories about Rocket Lab right now, and investors are struggling to reconcile them. On one side sits a $2.2 billion order book, a Japanese customer that keeps coming back for more, and a freshly inked $266 million contract with the US Space Force. On the other sits a stock that has shed 61.73% of its value since late May, closing at €51.20 on Wednesday — a world away from the €133.80 record high reached just weeks earlier.
The latest piece of good news came on Wednesday, when the company announced that Japanese radar-satellite builder iQPS had signed on for three more Electron missions starting in late 2027. That brings iQPS’s total booked launches with Rocket Lab to 18, making it a rare repeat customer in an industry that typically operates on one-off contracts. The stock responded with a 4.49% bounce to €53.50, but the relief rally barely scratches the surface of the damage done over the past month.
A Customer That Keeps Coming Back
Rocket Lab has now signed three multi-launch agreements with iQPS within a single year — an unusual pattern that speaks to the reliability of the Electron rocket. Since 2023, the company has successfully delivered seven iQPS satellites to orbit. Each of the upcoming missions will also use Rocket Lab’s proprietary Motorized Lightband separation systems, meaning the company collects revenue not just from the launch itself but from the hardware that goes along with it.
That vertical integration is a key part of the strategy. While SpaceX dominates heavy lift with a $1.6 billion Space Force contract for 18 Falcon 9 launches, Rocket Lab has carved out a niche in what it calls “responsive space” — launches on demand. The company demonstrated that capability on June 19, 2026, when its “Victus Haze” mission for the US Space Force put a satellite into orbit with just 16 hours and 42 minutes of advance notice. Competitors typically need months for the same task, and that speed is making Rocket Lab an increasingly attractive partner for national security customers.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The Neutron Problem
But the operational wins are being overshadowed by a single, massive question mark: the Neutron rocket. The company is developing the larger launch vehicle at NASA’s Stennis Space Center in Mississippi, where it has been testing the Archimedes engine. On July 14, engineers achieved a successful full-duration burn of the second stage — a genuine milestone. But the relief was short-lived.
The market hasn’t forgotten the manufacturing defect earlier this year that caused a fuel tank to rupture during a static-fire test. That setback, combined with the sheer ambition of trying to compete with SpaceX’s Falcon 9, has shifted the narrative around the stock. The dream of a “mini-SpaceX” has given way to the gritty reality of rocket development, where setbacks are expensive and delays are costly. Neutron’s first flight is still scheduled for the fourth quarter of 2026, but doubts about that timeline are weighing heavily on the valuation.
A $2.2 Billion Backlog That Can’t Stop the Bleeding
The disconnect between the order book and the share price is striking. Rocket Lab’s backlog climbed past $2.2 billion by May 2026, driven by a deliberate shift away from individual launches toward long-term government and defense contracts. The company is now a supplier to Raytheon on the Space Based Interceptor program for the US Department of Defense, embedding its propulsion and bus technology deeper into America’s missile defense architecture. On July 27, it added another $266 million contract for 12 suborbital HASTE missions to test hypersonic technology.
First-quarter revenue hit a record $200.3 million, and the company beat expectations with a loss of $0.07 per share. The Space Systems division now accounts for a meaningful portion of that revenue, reflecting Rocket Lab’s evolution from a pure launch provider into a vertically integrated space infrastructure company.
Oversold or Justified?
From a technical perspective, the stock looks deeply oversold. The 14-day relative strength index has fallen to 29.2 — a level where selling pressure historically tends to ease. The 52-week RSI reading of 32.8 tells a similar story. At a market capitalization of €35.11 billion, the gap between price and business performance is wide enough that most analysts remain bullish. The average price target stands at €100.40, nearly double the current level.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
That suggests the market is pricing in short-term test risks rather than a fundamental reassessment of the long-term opportunity. High-growth, high-valuation stocks have been under pressure across the board in a risk-averse environment, and Rocket Lab’s 93% annualized volatility makes it an easy target for sellers.
The August 10 Checkpoint
The next major catalyst comes on August 10, when Rocket Lab reports quarterly earnings. Investors will be watching closely to see whether the flood of new contracts — including the Space Force deal and the iQPS expansion — is translating into cash flow improvements. Behind the scenes, development work on Neutron continues, and the first launch later this year will be the ultimate test of whether the company can overcome its early manufacturing stumbles.
For now, Rocket Lab remains a stock caught between two realities. One is a growing, vertically integrated space company with a loyal customer base and a government-backed order book. The other is a high-risk development story where a single rocket failure could reset the timeline by months or years. The market has chosen to focus on the latter. Whether that changes depends on what happens in Mississippi — and on the launch pad — in the months ahead.
Ad
Rocket Lab Stock: New Analysis - 30 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
